Engineering T-cell Therapies to Survive Beyond Immunosuppressive Barriers Using Multiplex Prime Editing
Background
Cell therapies and gene therapies have recently garnered attention in the medical field as alternatives to overcome the limitations of existing treatments. However, these therapies lack practical control mechanisms to selectively regulate therapeutic cells within the patient's body. This limitation is particularly critical for patients who require continuous immunosuppressive therapy, such as those undergoing organ transplantation and receiving chimeric antigen receptor (CAR) T-cell therapy. In these cases, both the patient's pathogenic cells and the administered therapeutic T-cells are suppressed by the immunosuppressive effects, leading to severe consequences. Existing methods have been unable to preserve the activity of therapeutic cells in a drug-administered environment. Consequently, there is a need for a genetically engineered design that allows T-cells to fulfill their intended function even within the body's immunosuppressive signals.
Key Findings
To address these challenges, the researchers developed a multiplex prime-editing platform. Prime editing is a next-generation gene-editing technique that enables base substitution or insertion/deletion of desired sequences in the genome without inducing double-strand breaks. The researchers utilized this technology to propose a novel design that converts commonly used immunosuppressive agents into stimulators that promote the survival and activity of therapeutic cells. By manipulating specific drug delivery pathways, they programmed therapeutic T-cells to acquire resistance to immunosuppressants.
First, the researchers targeted genes associated with inherited immune dysregulation and simultaneously corrected multiple pathogenic variant sequences in primary human T-cells. In particular, they successfully corrected the HAVCR2 gene in T-cells from patients with subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Subsequent whole-genome and transcriptome analyses confirmed minimal off-target gene modifications, demonstrating the safety of the therapy.
Next, the researchers validated the efficacy of the cells in a humanized mouse model, mimicking the in vivo environment. They simultaneously introduced disease-correcting genes and immunosuppressant-resistance editing into T-cells from SPTCL patients and administered them to the animal model. When immunosuppressive drug pressure was applied to these animals, selective proliferation of the corrected T-cells was observed. Furthermore, the cells exhibited a safety switch function, rapidly undergoing apoptosis in response to alternative immunosuppressants, enabling rapid in vivo control.
Additionally, applying the same gene editing to antigen-specific T-cells and CAR T-cells demonstrated that they effectively maintained their inherent ability to kill cancer cells even under pharmacologic immunosuppression.
Significance and Prospects
This research establishes a logical framework for safely performing both immunosuppressive therapy and T-cell therapy, which have been difficult to combine. By elucidating the drug-regulating mechanism that helps artificial resistance cells survive in vivo, the researchers have paved the way for increasing the survival rate of therapeutic cells. In the future, this approach is expected to enable the safe and stable delivery of T-cell therapy to high-risk patients who require long-term immunosuppressant use, such as those undergoing kidney or liver transplantation.
However, there are challenges that need to be addressed before clinical application. Long-term monitoring is required to ensure that the survival rate observed in the mouse model is consistently reproduced in the complex microenvironment of the human body. Furthermore, overcoming genomic instability, such as chromosomal rearrangements that may occur during multiplex gene editing, is also a major challenge. If human safety can be demonstrated through clinical trials, the realization of personalized precision medicine will be further accelerated.
Current cell and gene therapies lack clinically practical mechanisms to selectively promote or suppress therapeutic cells in vivo, a limitation that is particularly acute in patients requiring ongoing immunosuppression. This includes gene therapy for immune dysregulation syndromes, and antigen-specific or chimeric antigen receptor (CAR) T-cell therapy for patients requiring immunosuppression (e.g., transplant recipients), where both pathogenic and therapeutic cells may be suppressed. Here, we develop a multiplex prime-editing platform that converts commonly used immunosuppressive drugs into tools for in vivo control of T-cell therapies via defined, pathway-specific drug resistance. Focusing initially on gene therapy, prime editing efficiently edited loci of multiple pathogenic variants associated with immune dysregulation in primary human T-cells and corrected the HAVCR2 driver mutation in T-cells from multiple patients with subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Comprehensive genomic, transcriptional, immunophenotypic, and clonal analyses demonstrated minimal off-target perturbation. Multiplexed gene correction and drug-resistance editing of T-cells from patients with SPTCL enabled selective in vivo expansion of corrected cells under immunosuppressive pressure in humanized mouse models and exhibited retained sensitivity to alternative agents permitting rapid in vivo suppression. Extending this approach, prime edited, drug-resistant antigen-specific and CAR T-cells retained effector function despite pharmacologic immunosuppression, demonstrating the generalizability of this platform to diverse cellular therapies. Together, these findings establish multiplex prime editing as a promising preclinical framework for generating drug-controllable T-cell therapies, enabling selective in vivo modulation in settings where immunosuppression cannot be withdrawn.
This gene-editing technology offers immediate therapeutic benefits to patients for whom immunosuppression to prevent graft rejection is a priority. For example, consider a scenario where CAR T-cells engineered using this technology are administered to a patient with end-stage cancer who has undergone kidney transplantation and is taking chronic immunosuppressants. Previously, drug interactions would have precluded immune cell therapy, but the application of this new therapy would allow for the concurrent performance of two therapeutic actions: preventing graft rejection and attacking cancer cells in the body.